2 min read

Abveris Announces Partnership with Nkarta using the Trianni Mouse on the Berkeley Lights Beacon

By Ryan Kelly on 5/12/20 8:08 AM

Click here to see the press release on BusinessWire.

Canton, MA, USA – Abveris, Inc. (“Abveris”) announced today that it has entered into an antibody discovery partnership with Nkarta, Inc. (“Nkarta”) for the discovery of fully-human monoclonal antibodies to support the advancement of Nkarta’s novel cell-based therapeutics. Under the terms of the agreement, Abveris will apply its next-generation B cell screening platform (powered by the Berkeley Lights Beacon®) to rapidly discover fully human monoclonal antibodies using the Trianni Mouse®, an industry-leading transgenic mouse R&D platform. 

“We have worked with the Trianni Mouse across several therapeutic antibody programs and have been impressed with the success of these campaigns,” commented Colby Souders, Ph.D., Chief Scientific Officer of Abveris. “Abveris is uniquely positioned to dramatically shorten therapeutic discovery timelines while enhancing candidate selection by pairing optimized immunization methods in the Trianni Mouse with high-resolution single B cell screening enabled by the Berkeley Lights Beacon.”    

Trianni

“We believe this partnership brings together powerful discovery technologies with the potential for accelerating Nkarta’s pipeline of natural killer cell therapy candidates,” said James Trager, Ph.D., Chief Scientific Officer of Nkarta. “We look forward to working closely with the Abveris team on the identification of targeted antibodies ideally suited for our cell engineering and manufacturing platform.”

Learn more:  B cell screening at Abveris

“The Nkarta team is situated to redefine the way we think about cell therapies, and we are delighted to be working with their team of impassioned scientists,” added Tracey Mullen, MBA, Chief Operating Officer of Abveris. “This partnership highlights our continued commitment to working with organizations leveraging antibody therapeutics in innovative and transformative ways.” 

"We at Trianni are thrilled that the partnership of Abveris and Nkarta includes the use of the Trianni Mice. It is gratifying to contribute to the program of creating novel antibody therapeutics," said Matthias Wabl, Ph.D., Chief Executive Officer of Trianni, Inc.

Get in touch with Abveris

About Abveris: 

Abveris is Boston's premier antibody discovery company providing contract research services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global leaders in biopharma. Additional information about Abveris is available at www.ABVERIS.com.

About Trianni, Inc: 

Trianni, Inc. is a privately held biotech company specializing in antibody discovery technology. Trianni’s lead technology, the Trianni Mouse®, is a powerful, next-generation platform enabling efficient generation of fully-human monoclonal antibodies. Trianni’s transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic modification technology. The company is headquartered in San Francisco, CA. Additional information about Trianni is available through its corporate website, www.TRIANNI.com.

 

Contact for Abveris:

Ryan Kelly

Director of Business Development

rkelly@abveris.com

781-562-1170 x1002

 

Contact for Trianni:

Elizabeth Tran

Marketing manager

elizabeth.tran@trianni.com

(415) 231-0257

 

Topics: Insider Press Releases
2 min read

Sustainable Science: Introducing Carbon-Neutral Shipping

By Matthew Bartolucci on 4/22/20 8:10 PM

Did you know that laboratory facilities often use 5-10x more energy compared to similarly-sized “normal” office spaces? Abveris is enacting sweeping changes to our laboratory and business operations to reduce our company's carbon footprint. 

In this post, we’ll detail our initiatives built to dramatically reduce the carbon cost of our shipping, including adopting carbon-neutral shipping methods and material reuse programs. We’ll share tips to implement similar changes at your company, too. 

 
Cold-chain shipping:
ESSENTIAL FOR RESEARCH & ENVIRONMENTALLY COSTLY 

Shipping is an important part of scientific collaborations today, which often extend beyond state and country lines. Since our founding five years ago, we’ve collaborated with scientists in more than 15 countries across four continents. For shipment of temperature-sensitive materials, we often rely on energy-intensive cold chain shipping methods that require additional packaging and refrigerants like ice packs, dry ice or liquid nitrogen. 

Initiative:
Carbon Offsets & Carbon-Neutral Shipping

Carbon offset programs allow small companies and individuals to participate in environmental projects to balance out their own carbon footprints. Abveris participates in verified carbon offset programs to support reforestation, landfill gas destruction, wastewater treatment, and methane destruction. 

You may be asking: how can I use carbon-neutral shipping?

Major shipping companies like UPS offer carbon-neutral shipping options. You'll be surprised to find that, often, the switch to carbon-neutral shipping will only impact shipment cost by $1 or less. 

Initiative:
Reduce, Reuse, Recycle

We are reducing our use of virgin materials by reusing the insulated shippers sent to us by our suppliers. We receive many high-quality insulated shipping containers used for the shipment of non-hazardous materials, like culture media.  Simply by reusing shipping boxes, we able to cut our use of virgin materials in half without sacrificing any quality of the materials we deliver to you.   

You may be asking: how can I start a box reuse program? 

Reusing a box should be easy in most BSL1 and BSL2 laboratory settings. Here are some quick tips to make sure you’re preparing the box appropriately to ship without issue:

  • Cover all outer box labels from the box's previous journey. 

    Cover all of the labels on the box, even those that might still be relevant. We recommend using blank white shipping labels to “white-out” and cover all of the stickers. Add the new box labels on top of the “white-out.”  This is important to ensure there are no delays in your shipment. 

  • When in doubt, throw it out.

    If the box is structurally compromised or potentially contaminated, it should not be reused. Only use boxes in good condition to keep your precious samples (and the people handling them) safe. 

  • For international shipments, it’s best to use new.

    During international shipping, it is best practice to present a tidy, clearly labeled product for customs agents. Additionally, for long distance shipments, it is important to select a container with well-defined limitations so you know how long the box will keep your samples cool. During long-distance journeys there may be limited opportunities for dry ice or ice pack replenishment. 

Topics: Green Initiatives
2 min read

FREE WEBINAR: High Throughput Antibody Discovery Targeting Cell Surface Receptors for Signaling Blocking in Cancer

By Travis LeGuyader on 4/14/20 3:11 PM

On-cell receptor functionality is a crucial threshold for drug development. By leveraging high content screening in antibody discovery workflows, you are able to improve the likelihood of campaign success at early stages of development. Join us for our webinar hosted by our COO Tracey Mullen and our friends at Sartorius, where Tracey will walk through a case study outlining how we incorporate this technology for antibody discovery projects targeting cell surface receptors. 

Tuesday, April 28, 2020, 11 am EDT

View on-demand webinar
 
Overview:

The use of monoclonal antibody-based therapeutics to target and treat cancer is considered to be one of the most successful therapeutic strategy within the oncology field to date. Specific cell surface antigen recognition is paramount to the success of these drugs, necessitating high resolution, early stage characterization of lead antibody drug candidates prior to preclinical development. In this webinar, Tracey Mullen, COO of Abveris, will review an antibody discovery campaign targeting a cell surface receptor implicated in cancer. Methods for immunization, antibody discovery, and subsequent functional characterization will be detailed.

Who Should Attend:
  • Antibody discovery scientists and researchers engaged in therapeutic drug discovery in oncology indications

  • Anyone interested in learning more about incorporating high-throughput flow cytometry analysis into early stage research and development

Speakers:
Tracey Mullen, Chief Operating Officer, Abveris

Tracey Mullen is a chemical-biological engineer from MIT who began her career as an Antibody Discovery Scientist at a startup contract research organization specializing in in vivo antibody discovery. In 2013, she joined the Antibody Discovery team at Biogen where she helped implement the technology transfer of the Adimab yeast display platform for antibody discovery and engineering. Throughout her tenure at Biogen, Tracey worked to optimize the in vitro discovery of antibodies to tough targets, including leveraging the Adimab platform to enerate antibodies against GPCRs. In June of 2018, Tracey joined Abveris Antibody as the Director of Antibody Discovery Operations, where she managed project design and development for in vivo discovery projects. She is now the Chief Operating Officer at AbX Biologics (formerly Abveris), a premium antibody discovery service partner boasting industry-leading timelines and cutting-edge technologies.

Carrie Haslam, Associate Editor, Select Science

Carrie Haslam is an Associate Editor at SelectScience, playing a key role in content production and specializing in Alzheimer’s disease and clinical diagnostics. She is finalizing her Ph.D. from Plymouth University, where she developed graphene-based biosensors for the early diagnosis of Alzheimer’s disease.

View on-demand webinar

Topics: Insider Service & Product Updates Events
2 min read

Free Webinar: Accelerating the antibody discovery workflow in the modern therapeutic landscape

By Ryan Kelly on 4/9/20 9:15 AM

How can we access greater antibody diversity through the plasma B cell repertoire? How can we down-select lead candidates in 1 day? Join Abveris and Berkeley Lights for an exclusive webinar opportunity to learn how we're redefining the boundaries of antibody discovery with the Berkeley Lights Beacon platform.

Tuesday, April 14, 2020, 11 am EDT

View on-demand Webinar
 
Overview:

As the complexity of therapeutic targets continues to evolve, more efficient and predictive identification of pertinent antibody candidates becomes increasingly valuable. Incorporating state-of-the-art, high-resolution discovery and characterization tools like the Berkeley Lights platform into discovery workflows enables rapid and reliable selection of lead candidates more effectively than traditional techniques. Elucidating function early during screening and development can enhance candidate triage, as opposed to relying on brute-force methods to characterize large panels containing primarily non-functional clones. Optimization of the discovery platform using the Beacon instrument and case studies will be outlined.

Speakers:
Colby A. Souders, Ph.D., Chief Scientific Officer, Abveris

Colby holds a PhD in Cell and Molecular Biology from Texas A&M and has spent the last decade focused on antibody research. He first joined MassBiologics to lead discovery programs, develop platform technologies and advance monoclonal antibodies in the pipeline for the prevention, treatment or diagnosis of infectious and endogenous diseases. He later joined the Kanyos Bio Protein Engineering team to develop therapeutics based on a novel antigen-specific immune tolerance platform. In 2018 Colby joined Abveris Antibody with the goal as Chief Scientific Officer to usher in new antibody discovery tools and build a premium discovery engine.

Anupam Singhal, Ph.D., Product Manager, Antibody Therapeutics, Berkeley Lights

Anupam Singhal earned his PhD from the University of British Columbia and has over 15 years of experience in nanotechnology and microfluidics at UBC, the University of Toronto and Stanford University. His work has been cited over 600 times and resulted in several patents for molecular disease diagnosis, antibody discovery, and development of production cell-lines for biologics. At Berkeley Lights, Anupam leads the development of next-generation platforms for the discovery and development of antibody therapeutics.

View on-demand Webinar

Topics: Insider Service & Product Updates Events
2 min read

Abveris and ACROBiosystems extend partnership

By Travis LeGuyader on 4/8/20 7:00 AM

Canton, MA, USA and Newark, DE, USA, April 8, 2020 - Abveris, Inc., a leader in contract research antibody discovery, today announced the extension of a strategic collaboration with ACROBiosystems, an internationally recognized manufacturer of recombinant proteins.

Under the terms of the agreement, the companies will leverage their core technologies to construct streamlined offerings to accelerate the pace of antibody discovery research.

Acro LogoBy the terms of the agreement, over 1600 recombinant proteins for biologic drug discovery and development available in the ACROBiosystems catalog will be made available to Abveris customers to facilitate rapid initiation of antibody discovery projects.

1600+ reagents at your fingertips click here to view the acro catalog

"Our collaboration with ACROBiosystems is a highly valuable resource for Abveris and all of our partner companies,” commented Ryan Kelly, Director of Business Development at Abveris. "Our access to ACRO’s high-quality “off-the-shelf” reagents allows us to identify diverse, high affinity antibody clones in as little as one month total.”

“We are delighted to collaborate with Abveris, who shows their expertise in therapeutic antibody development. Their special DiversimAbTM platform and single B cell screening platform speed up the antibody generation process while providing maximum diversity and affinity of the antibody candidates. It delivers additional benefits and comforts to scientists with using ACRO’s high-quality reagents and Abveris’s technologies as a combination,” commented Simin He, Marketing Manager of ACROBiosystems.

LET'S GET STARTED ON YOUR ANTIBODY PROJECT CLICK HERE TO INSTANTLY SET UP A CALL.

About Abveris: 

Abveris is a Boston-area specialty antibody discovery contract research organization located in Canton, Massachusetts, USA. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology. Additional information about Abveris is available at www.abveris.com.

About ACROBiosystems: 

ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application-oriented development strategy, with a particular focus on product design, quality control and solution-based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process. Check out more details at: www.acrobiosystems.com/.

Contact for Abveris:

Ryan Kelly

Director of Business Development

rkelly@abveris.com

781-562-1170 x1002

Contact for ACROBiosystems:

Grace Wang

Marketing Specialist

Grace.wang@acrobiosystems.com

408-320-2195

 

Topics: Insider Service & Product Updates
1 min read

Staying Open for Science, COVID Response

By Ryan Kelly on 3/20/20 12:44 PM

Abveris, Inc. 

March 18, 2020
RE: Staying Open for Science, COVID Response

 

To Our Valued Customers & Partners,

The COVID outbreak has caused significant disruptions to the science community worldwide, and your ongoing antibody discovery projects shouldn’t cause additional stress. Abveris will remain open for business and continue to provide contract research services during the state of emergency even if a "shelter-in-place" order is called. 

Abveris has multiple ongoing projects that directly contribute to drug development efforts for underserved diseases and indications (including COVID-19 and multiple other viral agents). Our end-to-end antibody discovery services are fully operational and we’re accepting new hybridoma and B cell screening discovery projects. Are you delaying your discovery work because of COVID-related antigen production delays? We can help.

Schedule 15 minutes with us today to discuss your project.

We are closely monitoring communications from the Massachusetts State and Federal Governments regarding measures to prevent the spread of the virus. Abveris has implemented mandatory work-from-home policies for non-essential staff, and employee schedules have been adjusted to promote social distancing. 

We welcome you to lean on us during these turbulent times. As always, we look forward to supporting your science.

 

Sincerely,

Garren Hilow

CEO of Abveris

 

Adversity has the effect of eliciting talents,

which in prosperous circumstances would have lain dormant

- Horace

Topics: Insider Press Releases Service & Product Updates
1 min read

Hey, Boston & Cambridge!  We're hosting a free happy hour!

By Travis LeGuyader on 2/12/20 7:30 AM

Updated 3/6/20: Event cancelled due to concerns surrounding spread of COVID-19 virus. 
A note from the event organizers:
Thank you for your interest in our event, and we apologize that we must postpone the happy hour indefinitely due to concerns surrounding the spread of Covid-19 infection. 
We're proud to announce that we had over 100 attendees registered a week ahead of the event. When the time is right, we will announce a revised event date. 

Thursday | March 12 | 5:00-7:30 PM | Cambridge, MA

Open Bar & Free Appetizers

What is Brews & Biopharma?

A free happy hour for biopharma scientists.

An exclusive, relaxed event for biopharma scientists in the protein sciences. Finish your workday (and start your night) with us over casual drinks, appetizers, and networking.

Who is invited?

Scientists from our partner companies and their invited guests*

*We kindly ask you not to invite your professional recruiter or salesperson friends as your guests. Nobody likes to be pitched after work. Thank you for respecting our policy. 

Topics: Insider Events
1 min read

Sustainable Science: Introduction to Our Green Initiatives Blog

By Matthew Bartolucci on 2/7/20 7:30 AM

 
Abveris is excited to announce our new Green Initiatives blog series.
Why are we “green-ing” our operations?


We are a group of biopharmaceutical scientists advancing a scientific mission to produce better biotherapeutic drugs. While our mission does not directly relate to environmental science, we recognize that environmental health ties directly to human health. Global climate scientists have reached a clear consensus: to address climate change, dramatic action must be taken now. To ignore our company’s contribution to global carbon emissions and climate change is irresponsible.

What’s the plan?

Abveris is enacting sweeping changes to our laboratory and business operations to reduce our company's carbon footprint. Did you know that laboratory facilities use 5-10x more energy compared to similarly-sized “normal” office spaces? As our lab continues to grow, we're scrutinizing our policies on energy use and sustainability so we can build valuable therapeutic products without leaving a harmful footprint.

Why are we blogging about it?

In this blog series, you’ll find information about our efforts to overhaul our company operations and move towards net carbon-neutrality. These initiatives extend beyond our laboratory and office to build support for eco-conscious behaviors at work, at home, and in our supply chain. By showcasing what we are doing in our labs and offices, we hope that other pharmaceutical scientists can follow our progress and enact changes in their own companies and institutions.

In each of our posts, we’ll break down the following:
  • What specific action are we taking to address climate change?
  • Why are we making a change?
  • What's the implementation strategy?
  • How do we expect to make an impact?
  • How can you, the reader, make a similar change in your own company?

Check out this blog series at abveris.com/greenscience to stay updated on our progress!

Topics: Green Initiatives
1 min read

WEBINAR: Integrating Octet into Early Antibody Discovery Workflows

By Ryan Kelly on 1/8/20 3:14 PM

Date: January 29, 2019 at 10AM ET (7AM PT)

Please join FortéBio and Abveris for an exclusive webinar featuring Colby Souders, Chief Scientific Officer of Abveris, who will review ways to utilize Octet screening to streamline antibody discovery projects.

View on demand Webinar

 

Who should attend:
  • Antibody discovery scientists and researchers engaged in therapeutic drug discovery.
  • Anyone interested in learning more about leveraging high-throughput Octet screening analyses to advance research and development.

Overview:

Integrating Octet into Early Antibody Discovery Workflows

Colby Souders, Chief Scientific Officer, Abveris

As industry-wide advancements in antibody drug discovery continue to push toward larger panels of candidates for early-stage characterization, more efficient identification of lead molecules through enhanced screening resolution is required. Integrating instruments like the Octet into the overall characterization workflow enables reliable, high throughput selection of lead candidates more effectively than alternative traditional techniques. This presentation will highlight a few unique methods of Octet utilization as a replacement or supplemental tool for various antibody discovery protocols. Comparisons across platforms, including traditional ELISA, flow cytometry, SPR, and in vivo studies will be presented.

 

View on demand Webinar

Topics: Insider
1 min read

COO of Abveris, Tracey Mullen, to Present at Antibody Engineering 2019 in San Diego

By Travis LeGuyader on 12/3/19 1:49 PM

December 9, 2019 – San Diego, CA - Are you attending the upcoming Antibody Engineering and Therapeutics conference in San Diego on December 9th? It’s not too late to sign up and spend some time in the sun while staying updated on the latest antibody discovery technologies and engineering techniques while networking with lead scientists in the antibody discovery world.

Join us on December 12 at noon for a scientific briefing led by Tracey Mullen, our Chief Operating Officer. Or, stop by our booth or posters in the exhibit hall and meet with Garren (CEO), Ryan (Director of Business Development) and Travis (Business Development Associate). See you there!

Click here to schedule an appointment with our team at the conference.

 

Information on our Scientific Briefing:
Scientific Briefing: Antibody Discovery for Traditionally Difficult Targets: in vivo, in vitro, or both?

Abstract: Leveraging the natural immune repertoire for antibody discovery has distinct advantages for positive downstream outcomes, including efficacy, developability and safety; however, traditional techniques typically fail to produce a productive response in situations where, for example, the target epitope has poor immunogenicity or is a rare, cryptic site. While some in vitro platforms can overcome these difficulties through careful guiding selection methods, significant downstream engineering is often required to ensure lead candidates harbor appropriate development qualities. Fortunately, recent advancements in protein engineering and antibody discovery have enabled improved drug development to these traditionally difficult targets. Using the AbX platform, the power of the immune system is harnessed to exemplify the breadth and comprehensive nature of the B cell repertoire. When applied to the most difficult target classes, lead candidates can be uncovered where traditional in vivo platforms typically fail, or significant engineering is required for in vitro discovery.

About the Antibody Engineering Conference: Antibody Engineering is the #1 antibody engineering conference for accelerating next-generation antibodies to commercial success. Find the latest science, technology, and partners in antibody engineering, immunobiology, and next-generation binders.

 

Antibody Engineering Logo

 

Topics: Conferences

Featured